MICC:NYSEThe Magnum Ice Cream Company N.V. Analysis
Data as of 2026-07-01 - not real-time
$18.09
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
The stock is trading at $18.09, just shy of the calculated resistance of $18.16 and comfortably above the 20‑day SMA of $17.30, indicating a short‑term price ceiling. Technical momentum remains bullish with the 20‑day SMA above both the 50‑day ($15.93) and 200‑day ($15.87) averages, while the RSI sits at 64.9, suggesting strength but no imminent overbought condition. However, the MACD histogram is negative and the signal line is labeled “bearish,” hinting at a possible near‑term pullback. Volume is on an increasing trend and beta is low at 0.43, which tempers market‑wide volatility, though the 30‑day realized volatility of 31.8% signals sizable price swings. Fundamentally, the company carries a heavy debt load (Debt‑to‑Equity > 500) and its DCF fair value of $3.05 is far below the current price, making the equity appear overvalued with a modest upside‑downside metric of –3.1%. Revenue has contracted 4.1% YoY, but margins remain respectable (gross 34.6%, operating 10.1%) and free cash flow of $365 M supports ongoing operations. Recent news highlights solid Q1 sales growth and a reaffirmed outlook, while whispers of interest from Blackstone and CD&R add a potential acquisition catalyst. Balancing the strong brand portfolio against high leverage and a valuation gap suggests caution in the near term, but the long‑run narrative could improve if a strategic transaction materializes.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 6/10
Key Factors
- Price approaching resistance with bearish MACD signal
- DCF valuation far below market price
- High debt-to-equity ratio increasing financial risk
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- Stable free cash flow and solid operating margins
- Potential acquisition interest from private‑equity firms
- Improving earnings outlook and reaffirmed guidance
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong brand portfolio with global reach
- Long‑term cash generation capability despite leverage
- Possible strategic transaction that could unlock value
Key Metrics & Analysis
Financial Health
Revenue Growth-4.10%
Profit Margin3.70%
P/E Ratio32.9
ROE17.88%
ROA8.72%
Debt/Equity539.65
P/B Ratio15.6
Op. Cash Flow$483.0M
Free Cash Flow$365.6M
Technical Analysis
TrendBullish
RSI65.0
Support$16.05
Resistance$18.16
MA 20$17.30
MA 50$15.93
MA 200$15.87
MACDBearish
VolumeIncreasing
Fear & Greed Index91.8
Valuation
Fair Value$3.05
Target Price$17.53
Upside/Downside-3.12%
GradeOvervalued
TypeValue
Risk Assessment
Beta0.43
Volatility31.84%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.